ARA-290 (PyroGlu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser) is a first-in-class, non-erythropoietic EPO derivative developed by Araim Pharmaceuticals. It selectively binds the tissue-protective innate repair receptor (IRR = EPOR-β common receptor complex) to provide potent anti-inflammatory, anti-apoptotic, and tissue-repair effects without raising hemoglobin or red blood cell count. Completed Phase 2 trials in sarcoidosis, type 2 diabetes neuropathy, and small-fiber neuropathy showed significant pain reduction and nerve regeneration with an outstanding safety profile.
Key Scientific Features
- High-purity ARA-290 (≥ 99% by HPLC/MS, acetate salt form)
- Verified 11-amino-acid sequence: pyroGlu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser
- Lyophilized formulation for maximum long-term stability
- Full Certificate of Analysis (COA) with HPLC, MS, amino acid analysis, and IRR binding assay
- Manufactured in GMP-aligned, ISO-compliant facilities
- Ideal for IRR activation, neuropathic pain, and tissue-protection research
Research-Referenced Attributes (Based on clinical & preclinical literature; not therapeutic claims.)
- Phase 2 sarcoidosis small-fiber neuropathy (n=64): 4 mg daily SC × 28 days → 50% reduction in neuropathic pain (NPS score)
- Phase 2 diabetic neuropathy (n=48): significant corneal nerve fiber density ↑ and pain ↓ vs. placebo
- Reduces HbA1c and improves metabolic parameters in T2D models
- Potent anti-inflammatory (↓ TNF-α, IL-6) and tissue-repair effects without erythropoiesis
- Excellent safety — no hemoglobin increase even at 8 mg daily for 56 days
- Valuable in sarcoidosis, diabetic neuropathy, autoimmune disease, and chronic pain research
Why Researchers Choose Nationwide Peptides ARA-290
- Exact clinical-sequence match used in all Phase 2 trials
- Highest documented IRR selectivity and pain-relief potency among suppliers
- Transparent analytical data (HPLC >99%, MS confirmation)
- Trusted by neurology, pain, and metabolic disease laboratories worldwide
- Competitive research pricing with bulk options
